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Abstract
Background: Manganese-enhanced cardiovascular magnetic resonance (MECMR) can non-invasively assess
myocardial calcium influx, and calcium levels are known to be elevated in muscular dystrophy cardiomyopathy
based on cellular studies.
Methods: Left ventricular functional studies and MECMR were performed in mdx mice (model of Duchenne
Muscular Dystrophy, 24 and 40 weeks) and Sgcd−/− mice (Limb Girdle Muscular Dystrophy 2 F, 16 and 32 weeks),
compared to wild type controls (C57Bl/10, WT).
Results: Both models had left ventricular hypertrophy at the later age compared to WT, though the mdx mice had
reduced stroke volumes and the Sgcd−/− mice increased heart rate and cardiac index. Especially at the younger
ages, MECMR was significantly elevated in both models (both P<0.05 versus WT). The L-type calcium channel
inhibitor diltiazem (5 mg/kg i.p.) significantly reduced MECMR in the mdx mice (P<0.01), though only with a higher
dose (10 mg/kg i.p.) in the Sgcd−/− mice (P<0.05). As the Sgcd−/− mice had increased heart rates, to determine the
role of heart rate in MECMR we studied the hyperpolarization-activated cyclic nucleotide-gated channel inhibitor
ZD 7288 which selectively reduces heart rate. This reduced heart rate and MECMR in all mouse groups. However,
when looking at the time course of reduction of MECMR in the Sgcd−/− mice at up to 5 minutes of the
manganese infusion when heart rates were matched to the WT mice, MECMR was still significantly elevated in the
Sgcd−/− mice (P<0.01) indicating that heart rate alone could not account for all the increased MECMR.
Conclusions: Despite both mouse models exhibiting increased in-vivo calcium influx at an early stage in the
development of the cardiomyopathy before left ventricular hypertrophy, there are distinct phenotypical differences
between the 2 models in terms of heart rates, hemodynamics and responses to calcium channel inhibitors.
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Background
Muscular dystrophies are frequently associated with cardi-
omyopathies. In Duchenne muscular dystrophy (DMD),
which is caused by the absence of dystrophin, either clin-
ical or subclinical dilated cardiomyopathy is invariably
present [1,2]. Recessive mutations in one of the genes for
α-, β-, γ- or δ-sarcoglycan cause a heterogeneous group of
autosomal recessive limb girdle muscular dystrophies
(LGMD2C-F), and these also frequently have dilated car-
diomyopathy, especially those patients with LGMD2F
caused by mutations in the δ-sarcoglycan gene [3].
A hypothesis to explain the underlying pathophysiology
of cardiomyopathies associated with muscular dystrophy
is that recurrent membrane injury leads to an increased
influx of calcium [4] which then causes downstream
effects such as activation of calcium-dependent hyper-
trophic pathways [5], reactive oxygen species [6] and cell
death through necrosis with mitochondrial defects [7].
Membrane injury may not be the only mechanism
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whereby calcium enters cardiomyocytes. Cohn et al. [8]
have shown that the L-type calcium channel antagonist
verapamil restores left ventricular function in Sgcd−/−
mice, though has no effects in mdx mice. Whereas this
was explained at that time on the basis of effects on coron-
ary vasculature, subsequent studies have suggested that this
was a direct cardiomyocyte effect [7,9]. That there are dif-
ferences between the Sgcd−/− and mdx mice has also re-
cently been highlighted by a study showing marked
hemodynamic differences in response to β-blockers [10].
Manganese-enhanced cardiovascular magnetic reson-
ance (MECMR) uses 2 properties of the manganese ion
to allow in-vivo assessment of calcium influx [11]. Man-
ganese enters cardiomyocytes through calcium channels,
and is also a T1 contrast agent with CMR. Thus,
increased calcium influx with dobutamine increases con-
trast-enhancement, and decreased influx with the cal-
cium channel blocker diltiazem reduces contrast. We
used MECMR to test the hypothesis that in-vivo calcium
influx in muscular dystrophy cardiomyopathy mice is
increased at an early stage in the development of the
cardiomyopathy and so is an important factor in disease
progression. To test this hypothesis we studied in-vivo left
ventricular function, and MECMR in Sgcd−/− and mdx
mice, determining the roles of ageing, L-type calcium
channel inhibition and heart rate in the altered manganese
contrast enhancement pattern of these models.
Methods
Animals: Two separate age groups of male mice were
used in this study. C57BL/10ScSnOlaHsd (wild type,
WT, Harlan Laboratories, Indianapolis, USA) and mdx
mice (C57BL/10ScSn-mdx/J, Jackson, Maine USA) were
scanned at ages 24 and 40 weeks, and Sgcd−/− mice
were scanned at 16 and 32 weeks (on C57Bl/6 back-
ground, a kind gift from Dr Kevin Campbell, University
of Iowa). These ages were chosen based on previous data
reflecting the earlier development of the cardiomyopathy
in the Sgcd−/− compared to the mdx mice [12,13].
Numbers of mice in the various experiments are detailed
in the table and figure legends. The investigation con-
forms with Directive 2010/63/EU of the European Par-
liament and was performed under the terms of the
Animals (Scientific Procedures) Act 1986, authorized by
the Home Secretary, Home Office UK. The Sgcd−/−
mice were compared with the 8 week older C57/BL10
mice as controls, as preliminary data showed no differ-
ences in any measure of left ventricular function or
manganese uptake between 16 and 24 week old C57/
BL10 mice (data not shown).
CMR
Mice were anaesthetized using 5% isofluorane and an-
aesthesia maintained at 1.5% in oxygen with a flow rate
of 0.5 L/min. The tail-vein was cannulated and mice
placed on a MR compatible sled with surface ECG elec-
trodes on the chest wall, respiration pillow and cutane-
ous temperature probe (Dazai Research Instruments,
MICe, Toronto, Canada). This was connected to MR
compatible monitoring equipment (SA Instruments Inc.,
Stony Brook, NY 11790). Mice on the sled were then
placed on a bed holding the nose cone for anaesthesia
delivery and then all of this slid into a 39 mm diameter
quadrature birdcage volume coil (Rapid Biomedical
GmbH). Images were acquired on a 7 Tesla horizontal
bore microimaging system equipped with a 12-cm microi-
maging gradient insert (maximum gradient 40 gauss/cm)
(Varian Inc., Palo Alto, CA, USA). Following power cali-
bration and global shimming a series of four pilot trans-
verse images were acquired over the heart. Single slice
coronal and sagittal images were then obtained in order to
view the apex and mitral valve planes. These images were
used to plan for the true short axis plane [14]. To measure
left ventricular function, contiguous short axis slices were
acquired to cover the entire left ventricle using a spoiled
gradient-echo cine sequence (TR=5 ms, TE=1.42 ms, flip
angle 15°, FOV 30×30 mm, data matrix 128×128, 1 mm
slice thickness, max. of 10 slices depending on heart size,
4 averages). Images were ECG triggered to the R wave with
a cine delay of 15 ms and typically 30 phases were acquired
distributed through the cardiac cycle (depending on HR).
Images were zero-filled to a matrix size of 256×256. Scans
were converted to matfiles (using a matlab script kindly
provided by Dr Johannes Riegler, University College
London, UK) and analysed using the freely available ana-
lysis software Segment v1.8 (http://segment.heiberg.se) [15]
to measure left ventricular mass and the LV functional
parameters – end-systolic and end-diastolic volumes,
stroke volume, ejection fraction and cardiac output.
Manganese enhanced CMR (MECMR)
For the manganese contrast enhancement, 60 mM man-
ganese chloride (Sigma-Aldrich 244589) was given by
intravenous infusion through the tail vein cannula at a
flow-rate of 0.6 ml/hour, flow time adjusted according to
weight to give a total dose of 190 nmol/g body weight.
For a 30 g mouse, this would result in a 9.5 minute infu-
sion. Gradient echo short axis images at the level of the
papillary muscles (T1 weighted parameters: TR=35 ms,
TE=3.5 ms, flip angle 60°, FOV 30 mm × 30 mm, data
matrix 128 × 128, 1 mm slice thickness, 6 averages) were
taken. Four baseline images were acquired in order to
average any variations due to changes in TR as a result
of fluctuations in heart rate and then at 5 minute inter-
vals for 50 minutes during and after manganese infusion.
A relative increase in T1 weighted contrast indicates
increased manganese uptake (Figure 1). Images acquired
from each timepoint were extracted using a Python
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script (kindly written by Dr Conor Lawless, Newcastle
University), opened in Image J (http://rsb.info.nih.gov/ij/)
and converted to a stack using the stack builder plugin. On
the first image an area of interest was drawn to fit inside
the myocardium and average signal intensity measured.
Minor adjustments of this drawn region were made for
subsequent images in the stack and the increase in myocar-
dial contrast enhancement expressed as a percentage in-
crease from the average of the four baseline images (which
showed little or no variation).
Pharmaceutical modification of manganese contrast
enhancement
The L-type calcium channel antagonist diltiazem
(5–10 mg/kg body weight i.p., 10 mg/kg being maximal
tolerated dose, Sigma Chemical Co., St Louis, MO)
was given separately to subgroups of the younger mice.
The hyperpolarization-activated cyclic nucleotide-gated
(HCN) channel inhibitor ZD 7288 (0.3 mg/kg body weight
i.p., Sigma Chemical Co., St Louis, MO) was also given to
separate groups to study the effects of selective heart rate
reduction on manganese contrast enhancement [16,17].
For the ZD 7288 experiments we also included a 2.5 minute
scan as we were particularly interested in the early kinetics
of manganese uptake related to heart rate. These medica-
tions were given prior to placing the animal in the scanner
which was approximately 30–40 minutes before the man-
ganese infusion.
Statistics
To test effects of time and age on manganese-contrast
enhancement, repeated measures of analysis of variance
was used combining data from young and old groups.
Within each age group, analysis of variance was used to
test differences amongst groups comparing an average
value of steady state manganese contrast enhancement,
and MR functional data. Post-hoc testing was performed
with the Scheffe′ test. Single comparisons were made
with Student’s t-tests. Data are expressed as mean ±
standard error of the mean.
Results
MR haemodynamics: Left ventricular hypertrophy in older
Sgcd−/− and mdx mice, increased heart rates and cardiac
index in Sgcd−/− mice, and reduced stroke volume in
mdx mice
Age had significant effects on haemodynamics (ANOVA,
all 3 groups combined), with significant increases in
end-diastolic volume (P<0.01), end-systolic volume, and
stroke volume (both P<0.05) (data not shown). As there
were significant differences in body weights, left ven-
tricular mass, volume measurements and cardiac output
are indexed to body weight (i.e. cardiac index), and with
that changes in volumes were no longer significant
(Table 1). Sgcd−/− mice had lower body weights, higher
heart rates, increased left ventricular mass index at the
older age, normal volumes, and increased cardiac index
at both ages. The increased cardiac index was a result of
the higher heart rate, as stroke volume index was not
significantly different to WT mice. The mdx mice had
significant left ventricular hypertrophy in the older age
group (though left ventricular mass index did not actu-
ally change in these mice with age, rather it was
decreased in older WT mice), and reduced stroke vol-
ume index when considering both age groups combined
compared to WT. The mdx mice also had significantly
lower ejection fractions compared to the Sgcd−/− mice.
Thus, there were markedly different haemodynamic char-
acteristics in the 2 muscular dystrophy mice models.
Whereas both had left ventricular hypertrophy at older
ages when compared to older WT, there was a hyperdy-
namic circulation in the Sgcd−/− mice with increased car-
diac index, and left ventricular systolic dysfunction with
reduced stroke volume in the mdx mice. Average surface
temperatures measured during the scans were not signifi-
cantly different between the groups (WT: 34.3±0.3°C, mdx
33.5±0.4°C and Sgcd−/− 34.3±0.3°C (ANOVA p=NS).
MECMR: Slower kinetics of manganese uptake in all older
mice, and increased contrast enhancement in younger
Sgcd−/− and mdx mice
Contrast-enhancement was significantly slower in all older
mouse groups compared to younger mice (Figures 2A and
B, P<0.05, time*age interaction, repeated measures
ANOVA combining both age groups and all 3 groups).
For instance, in older WT mice contrast-enhancement at
5 minutes was 29±5% compared with 53±5% in younger
WT mice. This analysis also showed that when
Figure 1 Representative figure showing single example of
manganese contrast enhancement experiment, with
superimposed images showing clear increase in myocardial
contrast following manganese infusion.
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considering both ages together contrast enhancement was
significantly elevated in the Sgcd−/− mice relative to con-
trols (P<0.05 post hoc Scheffe test), and this was of bor-
derline significance for the mdx mice (P=0.08). To study
contrast-enhancement within the 2 age groups, a mid
point value of contrast enhancement was defined as the
mean contrast enhancement of the steady state period of
10 to 25 minutes after start of the manganese infusion,
with 5 minute interval scans. In the older mice, mid point
contrast enhancement was borderline increased in the
Sgcd−/− compared to WT mice (P=0.07, post hoc Scheffe
test), and not significantly different in the mdx mice
(Figure 2C). In the younger mice, mid point contrast
enhancement was significantly increased in both the
Sgcd−/− and mdx compared to WT mice (both P<0.05,
post hoc Scheffe test). As the Sgcd−/− mice were on a dif-
ferent strain background to the C57Bl/10 controls we per-
formed initial experiments to determine if there was a
strain difference between C57Bl/10 and C57Bl/6 mice. In
these experiments the mid point contrast enhancement
was 50±6% in C57Bl/10 (N=5) and 50±10.0% in C57Bl/6
mice (N=3, p=NS) indicating that there was no strain
effect.
Pharmaceutical modification of calcium channels:
Resistance to L-type calcium channel blockade in young
Sgcd−/− mice
We concentrated on the younger mice for the pharma-
ceutical studies as these were the ages where the most sig-
nificant increases in contrast enhancement were seen. The
L-type calcium channel blocker diltiazem (5 mg/kg i.p.)
significantly reduced contrast enhancement (Figure 3A) in
WT (21%, P<0.05) and to a greater extent in mdx mice
(38%, P<0.001), though had no significant effects in the
Sgcd−/− mice (6%, P=NS). A higher dose of diltiazem
(10 mg/kg) did produce significant reductions in contrast
enhancement in Sgcd−/− mice (21%, P<0.05), indicating
that the L-type calcium channels were partially resistant
in the Sgcd−/− mice. Consistent with the variable sensitiv-
ity to L-type calcium channel blockade, diltiazem 5 mg/kg
significantly reduced heart rates in the WT and mdx mice,
but not in the Sgcd−/− mice, though 10 mg/kg did pro-
duce significant reductions in the Sgcd−/− mice
(Figure 3B).
The role of heart rate in manganese contrast
enhancement
There was increased contrast-enhancement in the Sgcd−/−
mice which accompanied a significantly higher heart rate
compared to WT mice (Table 1), and thus the mechanism
of this increased contrast-enhancement could be due to
more heart beats and action potentials transmitting Mn2+
into the cell, though could also be related to a cellular
channel defect with increased Mn2+ entry into the myo-
cyte per action potential. To clarify this issue we used the
HCN channel inhibitor ZD 7288 to selectively reduce
heart rate in all 3 groups of younger mice. ZD 7288 sig-
nificantly reduced contrast enhancement in all 3 groups
of mice, and this was associated with significant reduc-
tions in heart rate (Figure 4A and B). This does suggest
in general that the manganese contrast enhancement sig-
nal is sensitive to heart rate, and care must therefore be
taken when comparing mouse models with different heart
rates with this technique. However, when comparing the
time plots of contrast enhancement and heart rates in
the WT and Sgcd−/− mice (Figure 4C and D) we see that
at a very early stage in the increase in contrast enhance-
ment (2.5 and 5 minutes) when heart rates of both
Table 1 Haemodynamics in young and older mice
YOUNG OLD
WT Mdx Sgcd−/− WT Mdx Sgcd−/−
N 11 10 10 7 9 13
Body weight, g 33.3±0.9* 35.8±1.0** 28.8±1.0 40.5±1.2** 37.1±1.1 32.9±0.9
Heart rate, bpm 390±13** 419±14 480±14 384±16** 427±15 483±12
LV mass index, (×10-3) 3.03±0.12 3.57±0.13 3.58±0.13 2.80±0.14** 3.56±0.13+ 3.86±0.11
EDV index, μl/g 1.97±0.11 1.72±0.11 2.06±0.11 1.93±0.14 1.78±0.12 1.94±0.10
ESV index, μl/g 0.70±0.07 0.68±0.08 0.67±0.08 0.72±0.09 0.74±0.08 0.69±0.07
Stroke volume index, μl/g 1.28±0.06 1.03±0.06**/† 1.38±0.06 1.21±0.07 1.04±0.06† 1.25±0.05
Ejection fraction, % 65±2 61±2†† 68±2 63±3 60±2†† 65±2
Cardiac index, ml/min/g 0.50±0.03** 0.43±0.03** 0.67±0.03 0.46±0.03# 0.44±0.03** 0.60±0.03
LV: left ventricle; EDV: end-diastolic volume; ESV, end-systolic volume.
*P<0.01 vs older WT.
**P<0.01 vs Sgcd−/− within same age group.
+P<0.05 vs WT within same age group.
#P=0.06 vs Sgcd−/− within same age group.
† P<0.01 ANOVA vs WT and Sgcd−/− both ages combined.
†† P<0.05 ANOVA vs Sgcd−/− both ages combined.
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groups of mice are very similar that there was still a
marked increase in contrast-enhancement in the Sgcd−/−
mice compared to wild type. Thus, while contrast-
enhancement is sensitive to heart rate, by reducing the
heart rate in the Sgcd−/− mice to WT levels we can see
that there is clearly a component of increased cellular up-
take of Mn2+ per action potential. The pattern of early
increased contrast enhancement was not however seen
in the mdx mice. For instance, at 2.5 minutes with simi-
lar heart rates to WT mice contrast enhancement was
22±5% in the mdx mice compared to 17±6% in the WT
mice (p=NS), so this illustrates a different pattern to the
Figure 2 Effects of Ageing on Manganese Contrast Enhancement.
Manganese contrast enhancement in older mice (A) and young
mice (B). The kinetics of manganese contrast enhancement are
slower in the older mice compared to younger mice (P<0.05
repeated measures ANOVA). C. Mid point contrast enhancement in
older and younger mice. There was a borderline increase in contrast
enhancement in the older Sgcd−/− mice (#P=0.07 versus WT) and in
the younger mice contrast enhancement was significantly elevated
in both Sgcd−/− and mdx mice (+P<0.05 versus WT). For the
younger mice N as are in Table 1, in the older mice WT N = 9, mdx
N = 10, and Sgcd−/− mice N = 15 (as some older mice did not have
functional data).
Figure 3 Effects of L-type Calcium Channel Blocker Diltiazem
on Manganese Contrast Enhancement. A. Mid point contrast
enhancement in younger mice with no pharmacological treatment
(left column), showing significant higher levels of mid point contrast
enhancement in mdx and Sgcd−/− vs WT mice (+P<0.05 versus WT,
as in Figure 2C). Diltiazem 5 mg produced significant reductions in
contrast enhancement in mdx (N=7) and WT (N=6) versus no
treatment, though not for the Sgcd−/− mice (N=6). Diltiazem 10 mg
produced a significant reduction in contrast enhancement in the
Sgcd−/− mice (N=9); (+P<0.05 versus WT; *P<0.05 and **P<0.01
versus untreated, within same strain). B. Effects of diltiazem on heart
rates. Diltiazem (5 mg) significantly reduced heart rates in WT and in
mdx mice, though not in Sgcd−/− mice, a similar effect as seen with
manganese contrast enhancement. Higher doses of diltiazem
(10 mg) significantly reduced heart rates in the Sgcd−/− mice.
(*P<0.05 versus without diltiazem).
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Sgcd−/− mice, and potentially different mechanism of
abnormal contrast enhancement.
Discussion
In muscular dystrophy cardiomyopathy at an early stage
in the development of the cardiomyopathy before signifi-
cant left ventricular hypertrophy in both the mdx and
Sgcd−/− mouse models, in-vivo calcium influx is
increased (as determined by manganese contrast en-
hancement). However, there are clear differences in both
left ventricular function and myocardial calcium influx
between the 2 models. The mdx mouse has left ventricu-
lar systolic dysfunction with a reduction in stroke vol-
ume, whereas the Sgcd−/− mice have increased heart
rates, cardiac index and so a hyperdynamic circulation.
Ejection fractions are lower in the mdx compared to the
Sgcd−/− mice. These are also differences in the responses
to L-type calcium channel blockade in that there is a rela-
tive resistance in the Sgcd−/− mice though mdx mice ex-
hibit a similar response to wild type mice. As heart rate is
increased in the Sgcd−/− mice, this is potentially a cause of
the increased contrast enhancement, and selective heart
rate reduction reduces contrast enhancement in all groups.
Nevertheless, it is clear in the Sgcd−/− mice that when
heart rates are reduced to wild type levels, there is still
increased manganese contrast enhancement indicating a
primary cellular defect in calcium influx. This increase in
early contrast enhancement after heart rate reduction is
not seen with the mdx mice.
L-type calcium channels in muscular dystrophy
cardiomyopathy
We were interested in L-type calcium channel blockers
for 2 reasons – 1) they can reduce manganese contrast
enhancement [11], and 2) have differential effects in the
mdx and Sgcd−/− mice [8]. It is known that intracellular
calcium is increased in muscular dystrophy cardiomyop-
athy [7,18]. Cohn et al. [8] have shown that the L-type
calcium channel blocker verapamil had significant bene-
ficial effects in the Sgcd−/− mice on troponin I levels
and cardiac histology, though not in the mdx mice. To
reconcile the findings in this study and our findings it is
Figure 4 Effect of Heart Rate Reduction on Manganese Contrast Enhancement. A and B. The HCN channel inhibitor ZD 7288 significantly
reduced mid point contrast enhancement in all mouse groups (**P<0.01 versus without ZD 7288), and this was accompanied by significant
reductions in heart rate also in all groups (**P<0.01 versus heart rate pre ZD 7288) (WT N = 8, mdx N = 9, Sgcd−/− N = 10). C and D. When the
time course of manganese contrast enhancement and heart rate in the wild type and Sgcd−/− mice is examined we can see that the ZD 7288
reduces heart rate in the Sgcd−/− mice to the same level as wild type mice from the time of starting the manganese infusion, though during the
first 5 minutes there is still a significantly higher level of manganese contrast enhancement in the Sgcd−/− mice compared to WT (**P<0.01). This
indicates that whereas heart rate is an important factor in the extent of manganese contrast enhancement, in the Sgcd−/− mice there is at least
some component of increased cellular uptake of manganese per heart beat compared to WT.
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necessary to examine doses used. The doses used in
Cohn et al. compared to the present one are different
when corresponding human doses calculated by weight
are examined, though a consistent theme is that high
doses are required. The doses of diltiazem in the current
study of 5–10 mg/kg would equal 350–700 mg in a
70 kg human, the upper limit of a normal human dose
being 240 mg. The dose of verapamil used by Cohn
et al. was 3.5 mg/day, which would be approximately
35 fold higher than an appropriate human dose. One
possible consistent explanation is that only higher
doses of L-type calcium channel antagonists are effect-
ive in the Sgcd−/− mice, as we only show responses to
higher doses of diltiazem. There are strain differences
in the backgrounds of the wild type and mdx (both
C57Bl/10) versus the Sgcd−/− mice (C57Bl/6). Though
we could find no differences between Bl/10 and Bl/6
mice in terms of manganese uptake, we cannot rule
out some strain effect in the response to L-type cal-
cium channel blockade.
Role of heart rate in manganese contrast enhancement
When comparing models with different heart rates, it
may be difficult to determine whether a difference in
manganese contrast enhancement is due to the
increased heart rate resulting in more action potentials
over the period of the manganese infusion or whether
there is an underlying cellular defect with an altered cal-
cium influx per action potential [19]. To determine
whether the increased heart rate in the Sgcd−/− mice
accounts for the increased manganese contrast enhance-
ment we have used the HCN channel inhibitor ZD 7288
which inhibits the If channel producing a selective re-
duction in heart rate [16,17]. These studies clearly show
that at matched heart rates, the Sgcd−/− mice have
increased manganese contrast enhancement compared
to wild type, indicating a primary cellular defect in cal-
cium influx. These experiments also show clearly the im-
portant role that heart rate plays in manganese contrast
enhancement, so that for instance, in our experiments
with diltiazem it is reasonable to assume that some of
the reduction in contrast enhancement is due to a re-
duction in heart rate. Of note, a small amount of cal-
cium may enter cardiac myocytes through the If channel
(0.5% of the current from the HCN2 channel) [20],
though this small amount is unlikely to have significantly
effected our results. Furthermore, as the mdx mice do
not have significantly different heart rates compared to
wild type mice the increase in manganese contrast en-
hancement will be due to a primary cellular defect in
calcium influx. Surface temperatures of the mice were
below physiological levels during the scans, and so heart
rates were also low. Surface temperatures are approxi-
mately 1°C lower than core body temperature [21].
Higher temperatures would have likely resulted in higher
heart rates and this may alter manganese uptake rates.
Age-related changes in myocardial calcium influx
Isenberg et al. [22] have shown that in aged mice cal-
cium transients peak late and decay slowly. Salameh
et al. [23] have shown that the L-type calcium (ICa.L)
current is abnormal in aging rabbit hearts with the ICa.L
density normalised to cell volume significantly reduced,
maximum conductance also significantly decreased and
steady state inactivation shifted to more positive poten-
tials in aged hearts. However, expression of the α1c sub-
unit of the L-type channel, the SERCA2a-ATPase, and
the Na+/Ca2+ exchanger did not differ significantly be-
tween the two age groups. Direct comparison of cellular
calcium handling and MECMR would be very inform-
ative in studying age-related changes in calcium influx.
Our young and old mice were separate groups and in fu-
ture, serial MECMR studies within the same mouse will
also be important.
Left ventricular function in mouse models of muscular
dystrophy cardiomyopathy
We have previously shown that there are differences in
function between the mdx and Sgcd−/− mouse models
using the conductance catheter [10], and these results
are very consistent despite the very different techniques,
though adding information about left ventricular mass
and calcium influx. Townsend et al. [24] have compared
these mouse models and also found distinct differences
(at 6 – 8 months of age). Isolated myocytes from the
mdx mice show reduced compliance and are susceptible
to terminal contracture, whereas the Sgcd−/− mice had
normal compliance. There was increased fibrosis in the
Sgcd−/− hearts, though not in the mdx. We have also
shown that mdx mice exhibit improved hemodynamics
with 8 weeks of β-blocker treatment though there is sig-
nificant deterioration in the Sgcd−/− mice with reduced
heart rate, cardiac output and impaired active relaxation
[10]. Despite this information a specific molecular path-
way by which these differences occur is still unclear.
Conclusions and clinical relevance
We have shown at an early stage in the development of
muscular dystrophy cardiomyopathy that in-vivo calcium
influx is increased. Increased calcium influx and left ven-
tricular hypertrophy are seen in both models, though other
important haemodynamic and pharmacological differences
are apparent, so that all these factors need to be consid-
ered together when assessing mechanisms of the cardio-
myopathy and response to therapies. A limitation of
these in-vivo techniques is that it is difficult to say defini-
tively if there are specific abnormalities in channels such
as the L-type calcium channel in these models. Thus, the
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future utility of these non-invasive in-vivo techniques will
likely be in serially assessing responses to novel preclin-
ical treatments.
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